REM3
COURTESY REMINDER - SEC. 71 (6-YR) E-MAILED
10/27/2025
Back to search
Official data from USPTO
LUOXIN PHARMACEUTICAL
Did you know this trademark is already registered in United States?
Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.
Active USPTO registrationType: CombinedOffice: United States
Risk and opportunity diagnosis
Executive reading for naming, filing, and monitoring decisions.
USPTO status
Active USPTO registration
Case type
Application and registration
Recorded events
39
Latest update
10/28/2025
Trademark type
Combined
Nice classes
5
Filing date
07/18/2019
Registration date
10/27/2020
Expiration date
-
Complete case details
Structured fields from the responsible authority and the official record.
Status date
10/27/2020
Last transaction
10/28/2025
Responsible office
United States Patent and Trademark Office
Status code
700
Official register
Principal Register
Drawing code
3
Owner type
99
Owner location
Shandong, CN
Examiner
LAVACHE,LINDA M
Law office
L60
Current location
PUBLICATION AND ISSUE SECTION
Mark description
The mark consists of a design comprising two intersecting curved bands with horizontal stripes that form a Y-shaped figure. Above this design is an eight-pointed star. Two non-Latin characters appear, respectively, on the left and right of the bottom of the design. To the right of the foregoing elements are four non-Latin characters in horizontal arrangement above the wording "LUOXIN PHARMACEUTICAL" in stylized lettering.
Holders and representatives
Holders
SHANDONG LUOXIN PHARMACEUTICAL GROUP STOCK CO., LTD.
Representatives
Yue (Robert) Xu Apex Attorneys at Law, LLP
Technical classification
Nice Classes
Class 5
Vienna Codes
No Vienna codes available.
Goods and services
Class 5
Pharmaceutical preparations for use in chemotherapy; pharmaceutical preparations and substances for the treatment of viralmetabolicendocrinemusculoskeletalcardiovascularcardiopulmonarygenitourinarysexual dysfunctiononcologicalhepatologicalophthalmicrespiratoryneurologicalgastrointestinalhormonaldermatologicalpsychiatric and immune system related diseases and disorders; pharmaceutical preparations for peripheral nervous system; medicinal tea; Chinese medicine nostrum in the nature of natural remedy preparations for the treatment of cardiovascular diseasehypertensionAlzheimer diseasedepressioncancerdiabeteslung diseaseliver diseasecerebral ischemiaprostate diseaseinfertilityrheumatoid arthritisimmune system diseasegastrointestinal disease; medicinal herbs; biochemical medicines for the treatment of pneumoniaurinary tract infectiongynecological infectionsskin and skin structure infectionsmeningitissepticemiacancerdiabetesprostate diseaseinfertilityrheumatoid arthritisimmune system diseasegastrointestinal disease; biochemical drugs for treatment of gastrointestinal diseases; antiseptics; dental lacquer; diapers for pets; medicinal alcohol; medicinal oils; amino acids for medical purposes
Publications
History of USPTO decisions and trademark events.
39 publications found
FINV
FINAL DECISION TRANSACTION PROCESSED BY IB
03/07/2021
XXSS
GENERIC MADRID TRANSACTION SENT TO IB
02/09/2021
XXCR
GENERIC MADRID TRANSACTION CREATED
02/09/2021
FICR
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
01/27/2021
R.PR
REGISTERED-PRINCIPAL REGISTER
10/27/2020
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
08/11/2020
PUBO
PUBLISHED FOR OPPOSITION
08/11/2020
GPNX
NOTIFICATION PROCESSED BY IB
08/07/2020
OPNS
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
07/22/2020
OP2R
NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
07/22/2020
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
07/22/2020
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
07/08/2020
XAEC
EXAMINER'S AMENDMENT ENTERED
07/08/2020
GNEN
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
07/08/2020
GNEA
EXAMINERS AMENDMENT E-MAILED
07/08/2020
CNEA
EXAMINERS AMENDMENT -WRITTEN
07/08/2020
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
06/16/2020
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
06/16/2020
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
06/08/2020
RFNT
REFUSAL PROCESSED BY IB
03/27/2020
GNRN
NOTIFICATION OF NON-FINAL ACTION E-MAILED
02/20/2020
GNRT
NON-FINAL ACTION E-MAILED
02/20/2020
CNRT
NON-FINAL ACTION WRITTEN
02/20/2020
DOCK
ASSIGNED TO EXAMINER
01/22/2020
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
12/26/2019
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
12/26/2019
ALIE
ASSIGNED TO LIE
12/23/2019
RFNT
REFUSAL PROCESSED BY IB
12/14/2019
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
12/08/2019
RFCS
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
11/27/2019
RFRR
REFUSAL PROCESSED BY MPU
11/27/2019
RFCR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
11/05/2019
CNRT
NON-FINAL ACTION WRITTEN
11/04/2019
DOCK
ASSIGNED TO EXAMINER
10/04/2019
MAFR
APPLICATION FILING RECEIPT MAILED
09/24/2019
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
09/18/2019
LIMI
LIMITATION FROM ORIGINAL APPLICATION ENTERED
09/17/2019
REPR
SN ASSIGNED FOR SECT 66A APPL FROM IB
09/12/2019
Continuous trademark protection
Get notified about every new filing that threatens LUOXIN PHARMACEUTICAL or your mark.
Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.